Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry. American heart journal Alviar, C. L., Li, B. K., Keller, N. M., Bohula-May, E., Barnett, C., Berg, D. D., Burke, J. A., Chaudhry, S., Daniels, L. B., DeFilippis, A. P., Gerber, D., Horowitz, J., Jentzer, J. C., Katrapati, P., Keeley, E., Lawler, P. R., Park, J., Sinha, S. S., Snell, J., Solomon, M. A., Teuteberg, J., Katz, J. N., van Diepen, S., Morrow, D. A., CCCTN Investigators 2024

Abstract

BACKGROUND: Risk stratification has potential to guide triage and decision-making in cardiogenic shock (CS). We assessed the prognostic performance of the IABP-SHOCK II score, derived in Europe for acute myocardial infarct-related CS (AMI-CS), in a contemporary North American cohort, including different CS phenotypes.METHODS: The Critical Care Cardiology Trials Network (CCCTN) coordinated by the TIMI Study Group is a multicenter network of cardiac intensive care units (CICU). Participating centers annually contribute =2 months of consecutive medical CICU admissions. The IABP-SHOCK II risk score includes age >73 years, prior stroke, admission glucose >191 mg/dl, creatinine >1.5 mg/dl, lactate >5 mmol/l, and post-PCI TIMI flow grade <3. We assessed the risk score across various CS etiologies.RESULTS: Of 17,852 medical CICU admissions 5,340 patients across 35 sites were admitted with CS. In patients with AMI-CS (n=912), the IABP-SHOCK II score predicted a >3-fold gradient in in-hospital mortality (low risk?=?26.5%, intermediate risk =52.2%, high risk?=?77.5%, p<0.0001; c-statistic=0.67; Hosmer-Lemeshow p=0.79). The score showed a similar gradient of in-hospital mortality in patients with non-AMI-related CS (n=2,517, p<0.0001) and mixed shock (n=923, p<0.001), as well as in left ventricular (<0.0001), right ventricular (p?=?0.0163) or biventricular (<0.0001) CS. The correlation between the IABP-SHOCK II score and SOFA was moderate (r2=0.17) and the IABP-SHOCK II score revealed a significant risk gradient within each SCAI Stage.CONCLUSIONS: In an unselected international multicenter registry of patients admitted with CS, the IABP- SHOCK II score only moderately predicted in-hospital mortality in a broad population of CS regardless of etiology or irrespective of right, left, or bi-ventricular involvement.

View details for DOI 10.1016/j.ahj.2023.12.018

View details for PubMedID 38190931